Publicaciones en colaboración con investigadores/as de University of Innsbruck (21)

2024

  1. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 25, Núm. 9, pp. 1135-1146

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)

    The Lancet Psychiatry, Vol. 10, Núm. 3, pp. 197-208

  3. Sudden-Onset Disaster Mass-Casualty Incident Response: A Modified Delphi Study on Triage, Prehospital Life Support, and Processes

    Prehospital and Disaster Medicine, Vol. 38, Núm. 5, pp. 570-580

2021

  1. Recovery of kidney function in patients treated with maintenance dialysis-a report from the ERA-EDTA Registry

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 36, Núm. 6, pp. 1078-1087

  2. Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome

    Leukemia, Vol. 35, Núm. 6, pp. 1745-1750

2020

  1. COVID-19-related mortality in kidney transplant and dialysis patients: Results of the ERACODA collaboration

    Nephrology Dialysis Transplantation, Vol. 35, Núm. 11, pp. 1973-1983

  2. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

    Kidney International, Vol. 98, Núm. 6, pp. 1540-1548

2019

  1. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 20, Núm. 6, pp. 862-876

2018

  1. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study

    The Lancet Psychiatry, Vol. 5, Núm. 10, pp. 797-807

  2. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study

    European Psychiatry, Vol. 52, pp. 85-94

  3. Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance

    Genes Chromosomes and Cancer, Vol. 57, Núm. 11, pp. 547-556

  4. Correlates of sexual initiation among European adolescents

    PLoS ONE, Vol. 13, Núm. 2

  5. Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes

    Blood Advances, Vol. 2, Núm. 16, pp. 2079-2089

  6. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: A European LeukemiaNet study

    Leukemia, Vol. 32, Núm. 6, pp. 1380-1392

  7. Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS

    Leukemia Research, Vol. 67, pp. 21-26

2017

  1. Factors associated with different smoking status in European adolescents: results of the SEYLE study

    European Child and Adolescent Psychiatry, Vol. 26, Núm. 11, pp. 1319-1329

2015

  1. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

    British Journal of Haematology, Vol. 170, Núm. 3, pp. 372-383

2013

  1. Monosomal karyotype in MDS: Explaining the poor prognosis

    Leukemia, Vol. 27, Núm. 10, pp. 1988-1995

2012

  1. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

    Journal of Clinical Oncology, Vol. 30, Núm. 8, pp. 820-829